Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19291521 | 1.00 | KDM4E (0.49) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL25822216 | 0.89 | KDM4E (0.47) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL13881608 | 0.89 | KDM4E (0.47) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL25822208 | 0.87 | MTNR1A (0.44) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL25818072 | 0.87 | MTNR1A (0.44) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL4569077 | 0.87 | MTNR1A (0.44) | KDM4EMTNR1AMTNR1BGPBAR1CYSLTR1 | |
| SCHEMBL4569079 | 0.87 | MTNR1A (0.44) | KDM4EMTNR1AMTNR1BGPBAR1CYSLTR1 | |
| SCHEMBL19291587 | 0.87 | KDM4E (0.39) | KDM4ENSD2ALDH1A1SMN1; SMN2MTNR1A | |
| SCHEMBL4568807 | 0.86 | GPBAR1 (0.52) | MTNR1AMTNR1BHTR1DHTR1BGPBAR1 | |
| SCHEMBL4568788 | 0.86 | GPBAR1 (0.52) | MTNR1AMTNR1BHTR1DHTR1BGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KDM4E 2227/4885NSD2 2986/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.